Lysosomal acid lipase deficiency: Correction of lipid storage by adenovirus-mediated gene transfer in mice

Hong Du, Martin Heur, David P. Witte, Detlev Ameis, Gregory A. Grabowski

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal−/−) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal−/− mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50%, respectively, and cholesterol reductions of 55, 52, and 34%, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.

Original languageEnglish (US)
Pages (from-to)1361-1372
Number of pages12
JournalHuman Gene Therapy
Volume13
Issue number11
DOIs
StatePublished - Jul 20 2002
Externally publishedYes

Fingerprint

Cholesterol Ester Storage Disease
Wolman Disease
Sterol Esterase
Adenoviridae
Lipids
Genetic Therapy
Genes
Liver
Triglycerides
Hepatomegaly
Cholesterol Esters
Lysosomes
Intravenous Injections
Small Intestine
In Situ Hybridization
Hydrolysis
Spleen
Complementary DNA
Macrophages
Phosphates

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Lysosomal acid lipase deficiency : Correction of lipid storage by adenovirus-mediated gene transfer in mice. / Du, Hong; Heur, Martin; Witte, David P.; Ameis, Detlev; Grabowski, Gregory A.

In: Human Gene Therapy, Vol. 13, No. 11, 20.07.2002, p. 1361-1372.

Research output: Contribution to journalArticle

Du, Hong ; Heur, Martin ; Witte, David P. ; Ameis, Detlev ; Grabowski, Gregory A. / Lysosomal acid lipase deficiency : Correction of lipid storage by adenovirus-mediated gene transfer in mice. In: Human Gene Therapy. 2002 ; Vol. 13, No. 11. pp. 1361-1372.
@article{46a51f3849974ff9a7982f222d052324,
title = "Lysosomal acid lipase deficiency: Correction of lipid storage by adenovirus-mediated gene transfer in mice",
abstract = "Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal−/−) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal−/− mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50{\%}, respectively, and cholesterol reductions of 55, 52, and 34{\%}, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.",
author = "Hong Du and Martin Heur and Witte, {David P.} and Detlev Ameis and Grabowski, {Gregory A.}",
year = "2002",
month = "7",
day = "20",
doi = "10.1089/104303402760128586",
language = "English (US)",
volume = "13",
pages = "1361--1372",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Lysosomal acid lipase deficiency

T2 - Correction of lipid storage by adenovirus-mediated gene transfer in mice

AU - Du, Hong

AU - Heur, Martin

AU - Witte, David P.

AU - Ameis, Detlev

AU - Grabowski, Gregory A.

PY - 2002/7/20

Y1 - 2002/7/20

N2 - Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal−/−) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal−/− mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50%, respectively, and cholesterol reductions of 55, 52, and 34%, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.

AB - Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal−/−) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal−/− mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50%, respectively, and cholesterol reductions of 55, 52, and 34%, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.

UR - http://www.scopus.com/inward/record.url?scp=0036377803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036377803&partnerID=8YFLogxK

U2 - 10.1089/104303402760128586

DO - 10.1089/104303402760128586

M3 - Article

C2 - 12162818

AN - SCOPUS:0036377803

VL - 13

SP - 1361

EP - 1372

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -